Summit logo.png
Summit Therapeutics set to join Russell 3000® Index
June 08, 2021 07:00 ET | Summit Therapeutics Inc.
Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual...
Summit logo.png
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
June 03, 2021 08:00 ET | Summit Therapeutics Inc.
Cambridge, MA, June 03, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) invites our shareholders and other interested parties to attend our Company’s Annual Shareholders’ Meeting,...
Summit Master_rgb_png.png
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
May 18, 2021 07:00 ET | Summit Therapeutics Inc.
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against...
Summit Master_rgb_png.png
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
May 17, 2021 08:00 ET | Summit Therapeutics Inc.
Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021....
Summit Master_rgb_png.png
Summit Therapeutics Announces Closing of $75 Million Rights Offering
May 12, 2021 14:59 ET | Summit Therapeutics Inc.
Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results. The rights offering...
Summit Master_rgb_png.png
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
May 05, 2021 12:47 ET | Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight...
Summit Master_rgb_png.png
Summit Therapeutics Announces Commencement of Rights Offering
April 21, 2021 08:04 ET | Summit Therapeutics Inc.
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today...
Summit Master_rgb_png.png
Summit Therapeutics Announces Rights Offering
March 26, 2021 07:00 ET | Summit Therapeutics Inc.
Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the...
Summit Master_rgb_png.png
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
March 17, 2021 07:00 ET | Summit Therapeutics plc
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Cambridge, MA, March 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on...
Summit Master_rgb_png.png
Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
September 05, 2019 07:00 ET | Summit Therapeutics plc
Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference New Mechanism Antibiotic...